Several Classes of New Drugs Emerging for Parkinson Disease

Article Abstract:

Researchers discussed new treatments for Parkinson's disease at the 13th International Congress on Parkinson Disease. The treatment of Parkinson's disease was revolutionized back in the 1960s when a deficiency of dopamine in the brain was linked to the disease. Patients who were given a form of dopamine called levodopa recovered much of their function. However, levodopa has some serious side effects. Researchers have developed a new drug called ropinirole, which has fewer side effects. In one study patients taking ropinirole had half the risk of side effects as those taking levodopa.

---

Parkinson Disease in Twins: An Etiologic Study

Article Abstract:

There appears to be no genetic risk of Parkinson's disease unless the disease occurs before the age of 50. This was the conclusion of a study of 19,842 white male twins who were part of a World War II veterans registry. A total of 193 twins with Parkinson's disease were identified. However, the rate of Parkinson's disease in both twins was approximately the same among fraternal twins and identical twins. However, among 16 pairs of twins who developed Parkinson's disease before the age of 50, identical twins were six times more likely to develop the disease as fraternal twins.

Genetic aspects, Twins

---

Dopamine Agonists in Early Therapy for Parkinson Disease: Promise and Problems

Article Abstract:

Levodopa is effective in controlling abnormal movements in patients with Parkinson's disease but can have adverse side effects. Dopamine receptor agonists are a class of drug that seem to have fewer serious side effects but are less effective at preventing abnormal movements. Treatment should be individualized depending on the wishes of the patient.

Editorial, Pramipexole

Similar abstracts:

• Abstracts: Prevalence of Trichomonas vaginalis in men at high risk for sexually transmitted diseases. Comparative Prevalence of Infection With Trichomonas vaginalis Among Men Attending a Sexually Transmitted Diseases Clinic
• Abstracts: Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Assessing the benefits of antiretroviral therapy
• Abstracts: A framework for managing risk. Unity is strength in joint research project. What should I do about a colleague acting suspiciously?
• Abstracts: When is prescribing not prescribing? Job prescription. Nurse prescribing fails to deliver
• Abstracts: Canadian doctors unhappy at prescribing 'medicine'. Imaging metalloproteinase activity in vivo. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.